Tropical medicine

On-Device AI Healthcare Company Noul Becomes First Korean Diagnostic Company to Join Swiss Malaria Group

Retrieved on: 
Monday, February 12, 2024

The recognition of innovation in the malaria diagnostic solution, miLab™ MAL played a major role in Noul becoming an official member of the Swiss Malaria Group.

Key Points: 
  • The recognition of innovation in the malaria diagnostic solution, miLab™ MAL played a major role in Noul becoming an official member of the Swiss Malaria Group.
  • Dr. Taehwan Kim, Managing Director of noul GmbH said, "noul GmbH will play a pivotal role in global malaria diagnosis through its activities as a member of the Swiss Malaria Group.
  • Swiss Malaria Group said, "Noul's innovative diagnostic tools align perfectly with the Swiss Malaria Group's emphasis on innovative solutions in the fight against malaria.
  • Noul, which focuses on diagnostic solutions in blood and tissue diagnostics, has developed a cutting-edge digital microscopy-based malaria diagnostic tool, miLab™ MAL."

Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa

Retrieved on: 
Thursday, February 1, 2024

Commencement of Direct Sales Operations in Africa, and Establishment of Branch Office in Kenya

Key Points: 
  • Commencement of Direct Sales Operations in Africa, and Establishment of Branch Office in Kenya
    TOKYO, Feb 1, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd ("Eisai South Africa"), a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa.
  • Eisai South Africa is a wholly-owned subsidiary of Eisai.
  • Eisai South Africa has started sales and marketing activities directly for Lenvima and Fycompa from January 2024, as well as Halaven from February 2024.
  • Seeking solutions to these challenges in Africa, Eisai will continue its initiatives to deliver necessary medicines to the patients who need them through Eisai South Africa and Eisai Kenya.

CORBEVAX®, A COVID19 VACCINE DEVELOPED BY BIO E-INDIA BASED ON THE RBD PROTEIN ANTIGEN TECHNOLOGY FROM TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT, RECEIVES WORLD HEALTH ORGANIZATION EMERGENCY USE LISTING APPROVAL

Retrieved on: 
Monday, January 22, 2024

HOUSTON, Jan. 22, 2024 /PRNewswire/ -- Texas Children's Hospital announces today that Biological E's CORBEVAX®, a traditional, recombinant protein-based COVID-19 vaccine has received World Health Organization (WHO) approval under Emergency Use Listing (EUL). CORBEVAX® is developed and commercialized by Biological E Limited, an established global vaccine supplier based in Hyderabad, India, using Pichia pastoris yeast strain expressing Receptor Binding Domain (RBD) protein of SARS-CoV-2 engineered by Texas Children's Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine (BCM),

Key Points: 
  • "The recombinant yeast strains enable production of the RBD protein which can be further utilized by vaccine researchers globally to develop & manufacture effective and low-cost vaccines.
  • By providing access to the yeast strains via non-exclusive licensing, we continue our mission to support global vaccine accessibility and availability."
  • Biological E subsequently developed large scale manufacturing technology for production of the RBD protein complying with Good Manufacturing Practices (GMP) as well as testing & characterization suitable for use as vaccine antigen.
  • The RBD protein was then used as an antigen and formulated with optimized adjuvants (Alum and CpG1018) to develop a COVID-19 candidate vaccine.

THE AMERICAN ACADEMY OF COSMETIC SURGERY (AACS) MARKS ITS 40th ANNIVERSARY WITH A COMPREHENSIVE SCIENTIFIC MEETING, PRE-MEETING WORKSHOP, AND DIVERSE OFFERINGS

Retrieved on: 
Tuesday, January 16, 2024

CHICAGO, Jan. 16, 2024 /PRNewswire/ -- The American Academy of Cosmetic Surgery (AACS), the world's largest multi-specialty home for physicians dedicated to cosmetic surgery and aesthetic medicine, will present its 40th Annual Scientific Meeting (ASM) on February 22-24, 2024, with an optional pre-meeting workshop on Ultrasound for Safe Brazilian Butt Lift Surgery and More, on Wednesday, February 21.

Key Points: 
  • In celebration of the AACS' 40th Annual Scientific Meeting, and the 40-year anniversary of the formation of the Academy and its official publication, The American Journal of Cosmetic Surgery, the meeting includes a comprehensive scientific program, as well as an array of advocacy, enrichment, networking and 40th anniversary celebratory activities.
  • Offering 41 educational sessions , the 2024 AACS ASM features foremost experts spanning diverse background specialties, such as dermatology, otolaryngology, general surgery, oral, and maxillofacial surgery, ophthalmology, and plastic and reconstructive surgery.
  • J. Kevin Duplechain, MD, FAACS, cosmetic surgeon and Immediate Past-President of the AACS and Cosmetic Surgery Foundation, will deliver the prestigious Webster Lecture on Friday, February 23.
  • Cosmetic surgery practitioners may register here for the 2024 AACS ASM.

A UNIVERSAL CORONAVIRUS VACCINE COULD SAVE BILLIONS OF DOLLARS IF READY BEFORE NEXT PANDEMIC

Retrieved on: 
Thursday, January 11, 2024

NEW YORK, Jan. 11, 2024 /PRNewswire/ -- What if scientists had developed a universal coronavirus vaccine in the years prior to 2020 so that it was available at the start of the COVID-19 pandemic? A universal coronavirus vaccine targets parts of the virus that are common to either many or all coronaviruses, thereby offering some degree of protection against a range of strains. A new study suggests if such a vaccine were available at the start of the pandemic, it could have saved millions of lives, prevented suffering, and saved billions of dollars in direct medical and other costs until the strain-specific (i.e., SARS-CoV-2) vaccine went through the entire development, testing, and emergency use authorization process that lasted 10 months.

Key Points: 
  • NEW YORK, Jan. 11, 2024 /PRNewswire/ -- What if scientists had developed a universal coronavirus vaccine in the years prior to 2020 so that it was available at the start of the COVID-19 pandemic?
  • A universal coronavirus vaccine targets parts of the virus that are common to either many or all coronaviruses, thereby offering some degree of protection against a range of strains.
  • The experiments simulated what would happen if a universal coronavirus vaccine was available at the start of the COVID-19 pandemic.
  • A universal coronavirus vaccine was also shown to be highly cost-effective even if a more specific and more efficacious vaccine came to market.

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

Retrieved on: 
Friday, December 15, 2023

Sanofi, DNDi and the HAT-r-ACC consortium announce the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense).

Key Points: 
  • Sanofi, DNDi and the HAT-r-ACC consortium announce the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense).
  • rhodesiense sleeping sickness, an acute and lethal form of this parasitic disease found in Eastern and Southern Africa.
  • Sleeping sickness, or human African trypanosomiasis (HAT), is usually fatal without treatment.
  • Both forms of sleeping sickness are transmitted by the bite of infected tsetse flies, which are found in 36 African countries.

NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

Retrieved on: 
Monday, December 18, 2023

"Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have become increasingly resistant to commonly used antibiotics.

Key Points: 
  • "Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have become increasingly resistant to commonly used antibiotics.
  • New treatment options are urgently needed" stated Jonathan Javitt, MD MPH, Founder and Chief Scientist of NRx Pharmaceuticals.
  • "The D-cycloserine (DCS) component of NRX-101 is well known as an antibiotic and is excreted unmetabolized in the urine.
  • The company awaits the FDA's response to its request for Qualified Infectious Disease Product (QIDP) designation, expected next month.

Reckitt Global Hygiene Institute: Priority List Provides Governments with New Tool To Monitor and Improve Adolescent Menstrual Health and Hygiene

Retrieved on: 
Thursday, November 30, 2023

MADISON, N.J. , Nov. 30, 2023 /PRNewswire/ -- Researchers have developed a priority list of indicators to improve the monitoring of the menstrual health and hygiene (MHH) of adolescent girls in low- and middle-income countries (LMIC).

Key Points: 
  • MADISON, N.J. , Nov. 30, 2023 /PRNewswire/ -- Researchers have developed a priority list of indicators to improve the monitoring of the menstrual health and hygiene (MHH) of adolescent girls in low- and middle-income countries (LMIC).
  • "Despite the importance of menstrual health and hygiene for adolescent girls' health, education, and gender equality, few countries monitor MHH.
  • The priority list includes 21 indicators  including access to menstrual educational materials; the availability of water, sanitation, and hygiene (WASH) facilities; and policies.
  • "This priority list was developed to improve the monitoring of adolescent menstrual health and hygiene globally," said lead author Dr. Julie Hennegan, Reckitt Global Hygiene Institute (RGHI) fellow and senior research fellow at the Burnet Institute, an Australian-based medical research institute, where she also serves as co-head of the its Global Adolescent Health Working Group.

AI Diagnostic Platform Company Noul, unveils the result of Malaria study in Ethiopia and Ghana

Retrieved on: 
Monday, October 23, 2023

In the study, the scientists compared the sensitivity and specificity of the qPCR with those of miLab™, field microscopy, and Rapid Diagnostic Test (RDT) respectively.

Key Points: 
  • In the study, the scientists compared the sensitivity and specificity of the qPCR with those of miLab™, field microscopy, and Rapid Diagnostic Test (RDT) respectively.
  • Diagnosis of P. falciparum infections included cases with hrp2/hrp3 gene deletion with renders parasites 'invisible' to common rapid diagnostic tests.
  • Also, the diagnostic results of miLab™ in P. falciparum infected patients with hrp2/hrp3 gene deletion have been released.
  • This new study in Ethiopia and Ghana confirmed the clinical performance of miLab™ as a reliable new tool in the diagnosis of P. falciparum and P. vivax malaria.

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Retrieved on: 
Wednesday, October 11, 2023

Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023.

Key Points: 
  • Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023.
  • At IDWeek, the annual meeting of the Infectious Diseases Society of America (IDSA), Valneva will support the roundtable discussion “Chikungunya is an Increasing Global Threat: The Need for Better Protection” taking place on October 14, 2023 at 6:00 pm Eastern Daylight Time (EDT) in Boston, Massachusetts.
  • At the American Society of Tropical Medicine and Hygiene (ASTMH) 2023 Annual Meeting in Chicago, Illinois, Valneva will hold two chikungunya presentations on October 20, 2023 at 11:00 am and 12:15 pm Central Daylight Time (CDT).
  • At the International Society of Vaccines Annual Congress taking place in Lausanne, Switzerland Valneva will present on chikungunya on October 24, 2023 at 09:45 am Central European Summer Time (CEST).